2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human umbilical vein endothelial cells (HUVECs)

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

5

Peptides

1

Inhibitory Antibodies

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103316
    trans-Ned 19

    		Calcium Channel Cardiovascular Disease
    trans-Ned 19, a NAADP antagonist and TPC blocker, suppresses the calcium signal in human umbilical vein endothelial cells (HUVEC) and the rat aorta relaxation in response to low histamine concentrations .
    trans-Ned 19
  • HY-N6737
    Aureothricin

    		Bacterial Antibiotic Infection
    Aureothricin is a dithiolopyrrolone (DTP) antibiotic first isolated from Streptomyces and exhibits relatively broad-spectrum antibiotic activity. Aureothricin can inhibit adhesion of human umbilical vein endothelial cells (HUVECs) to vitronectin .
    Aureothricin
  • HY-P5877
    ɛPKC(85–92),Myristoylated

    		PKC Inflammation/Immunology
    ?PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC? peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .
    ɛPKC(85–92),Myristoylated
  • HY-P5888
    PKCε inhibitor peptide,myristoylated

    Myr‐PKCɛ-

    		 PKC Inflammation/Immunology
    PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated PKC? peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .
    PKCε inhibitor peptide,myristoylated
  • HY-149921
    Antiangiogenic agent 3

    		Others Cancer
    Antiangiogenic agent 3 (compound 3) is a potent antiangiogenic agent. Antiangiogenic agent 3 is an inhibitor of human umbilical vein endothelial cells (HUVEC). Antiangiogenic agent 3 inhibits HUVEC migration and chemotactic motilities. Antiangiogenic agent 3 also decreases the gene expression of Src, cdc42, and MAPK .
    Antiangiogenic agent 3
  • HY-W588250
    Surfactin C1

    		Integrin Inflammation/Immunology
    Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelial cells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1 .
    Surfactin C1
  • HY-W800162
    VEGFR-2-IN-37

    		VEGFR Cancer
    VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .
    VEGFR-2-IN-37
  • HY-125919
    Vulpinic acid

    		Reactive Oxygen Species Bacterial Endogenous Metabolite Infection Inflammation/Immunology
    Vulpinic acid, a lichen metabolite, decreases H2O2-induced ROS production, oxidative stress and oxidative stress-related damages in human umbilical vein endothelial cells (HUVEC). Vulpinic acid is active against staphylococci, enterococci, and anaerobic bacteria.Vulpinic acid has the potential for atherosclerosis research .
    Vulpinic acid
  • HY-W013557
    3-Hydroxyxanthone

    3-Hydroxy-xanthen-9-one

    		 Integrin Inflammation/Immunology
    3-Hydroxyxanthone (3-Hydroxy-xanthen-9-one) is a xanthone compound, with . 3-Hydroxyxanthone inhibits NADPH-catalysed lipid peroxidation in human umbilical vein endothelial cells (HUVECs). 3-Hydroxyxanthone also inhibits TNF-alpha induced ICAM-1 expression .
    3-Hydroxyxanthone
  • HY-N2927
    Costic acid

    β-Costic acid

    		 Parasite Infection
    Costic acid (β-Costic acid) is a natural product, that can be isolated from Dittrichia viscosa. Costic acid exhibits potent in vivo acaricidal activity against the parasite. Costic acid is not toxic for human umbilical vein endothelial cells (HUVEC) at concentrations of up to 230 μM. Costic acid can be used for the research of varroosis in honey bee colonies .
    Costic acid
  • HY-P99333
    Volociximab

    M200; Eos 200-4

    		 Integrin Cardiovascular Disease Cancer
    Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
    Volociximab
  • HY-13645
    Henatinib

    		VEGFR c-Kit PDGFR Cancer
    Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, c-kit, PDGFR with IC50 values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .
    Henatinib
  • HY-133924
    18-Deoxyherboxidiene

    RQN-18690A

    		 Others Cardiovascular Disease Cancer
    18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research .
    18-Deoxyherboxidiene
  • HY-120200
    YF-452

    		VEGFR Cardiovascular Disease Cancer
    YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .
    YF-452
  • HY-148877
    AT-533

    		HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK Infection Inflammation/Immunology Cancer
    AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .
    AT-533
  • HY-N0515
    Ophiopogonin D

    		PPAR NF-κB Calcium Channel Cardiovascular Disease Inflammation/Immunology
    Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca 2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .
    Ophiopogonin D
  • HY-155721
    22-(4′-py)-JA

    22-(4′-Pyridinecarbonyl) jorunnamycin A

    		 Akt mTOR Cancer
    22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .
    22-(4′-py)-JA
  • HY-P3522
    REDV

    		Integrin Cancer
    REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .
    REDV
  • HY-P3522A
    REDV TFA

    		Integrin Cancer
    REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .
    REDV TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: